Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. DaShenLin Pharmaceutical Group Co., Ltd.
  6. Summary
    603233   CNE100002RG2

DASHENLIN PHARMACEUTICAL GROUP CO., LTD.

(603233)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
39.5 41.28 40.1 39.58 38.05 Last
4321863 4031321 2758441 3077340 2845007 Volume
-4.47% +4.51% -2.86% -1.30% -3.87% Change
Estimated financial data (e)
Sales 2021 17 416 M 2 741 M 2 741 M
Net income 2021 1 088 M 171 M 171 M
Net cash position 2021 2 211 M 348 M 348 M
P/E ratio 2021 25,9x
Yield 2021 1,85%
Sales 2022 21 745 M 3 422 M 3 422 M
Net income 2022 1 424 M 224 M 224 M
Net cash position 2022 2 575 M 405 M 405 M
P/E ratio 2022 21,2x
Yield 2022 2,19%
Capitalization 30 096 M 4 728 M 4 736 M
EV / Sales 2021 1,60x
EV / Sales 2022 1,27x
Nbr of Employees 32 337
Free-Float 30,8%
More Financials
Company
DaShenLin Pharmaceutical Group Co., Ltd. is a China-based company principally engaged in the pharmaceutical retailing business. The Company's primary business includes direct sales and retailing of Chinese and Western medicine, ginseng nourishing herbs and Chinese medicine pieces, health products, medical apparatus and instruments and other commodities. The Company mainly conducts its business within domestic market. 
Sector
Drug Retailers
Calendar
04/28Earnings Release
More about the company
Ratings of DaShenLin Pharmaceutical Group Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about DASHENLIN PHARMACEUTICAL GROUP CO., LTD.
2021DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2021Dashenlin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2021Dashenlin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter..
CI
2021Dashenlin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year End..
CI
2020DaShenLin Pharmaceutical Group Co., Ltd. cancelled the acquisition of 51% stake in Nant..
CI
2020Dashenlin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2020Secretive High-Speed Trading Firm Hits Jackpot With TikTok
DJ
2020Dashenlin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year End..
CI
2020Certain A Shares of DaShenLin Pharmaceutical Group Co., Ltd. are subject to a Lock-Up A..
CI
2020DaShenLin Pharmaceutical Group Co., Ltd. Announces Cash Dividend for the Year 2019, Pay..
CI
2020Dashenlin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year End..
CI
2020DaShenLin Pharmaceutical Group Co., Ltd. cancelled acquisition of an additional 46% sta..
CI
2019DaShenLin Pharmaceutical Group Co., Ltd. signed an equity transfer agreement to acquire..
CI
2019Dashenlin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months E..
CI
2019Dashenlin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year End..
CI
More news
News in other languages on DASHENLIN PHARMACEUTICAL GROUP CO., LTD.
2020DaShenLin Pharmaceutical Group Co., Ltd. annonce un dividende en espèces pour l'année 2..
More news
Chart DASHENLIN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
DaShenLin Pharmaceutical Group Co., Ltd. Technical Analysis Chart | 603233 | CNE100002RG2 | MarketScreener
Technical analysis trends DASHENLIN PHARMACEUTICAL GROUP CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 38,05 CNY
Average target price 66,90 CNY
Spread / Average Target 75,8%
EPS Revisions
Managers and Directors
Guo Qiang Ke General Manager
Yun Feng Ke Chairman
Zhi Hui Chen Chairman-Supervisory Board
Guo Chang Liu Independent Director
Xiao Qiang Yang Independent Director